DE | EN

IPrime . Top-Quality Intellectual Property Services with a Wealth of Experience

IPrime Rentsch Kaelin Ltd / IPrime Huhn Sparing Patentanwaltsgesellschaft mbH

Patent Attorneys and Attorneys at Law – Boutique for Patents and Trademarks as well as ICT and Technology Law

Agility, Specialisation and Globalisation define today’s basic framework of requirements from Patent Law and Intellectual Property Law in general. We support you with our experience in these sectors.

Technology and law are subject to accelerated change. Opportunities for optimised Intellectual Property Right (IPR) strategies are closely linked to the risks of competition.

IPrime's patent attorneys and attorneys at law focus on the needs of strategically oriented industrial companies, technology leaders and start-up companies, while working closely alongside research labs and universities.

IPrime employs Swiss, German and European patent attorneys with an education in engineering and natural sciences, who work regularly alongside our specialised lawyers. Our international network with leading law firms allows us to support you in Switzerland, and also in complex, cross-border strategic matters involving IPR protection and prosecution abroad.

A main area of our activity covers legal advice in the fields of industrial production and manufacturing technologies, chemistry and medical technology, robotics, cybertechnology and energy engineering. We also regularly advise in the areas of copyright, information and communication technology (ICT), licensing and competition law.

IPrime stands for the highest quality and precision of service. The customer orientation and focus of our consultations and services reflect our principles, which we stand by with our many years of experience.

News

01.09.2018
New Attorney at Law at IPrime
Ronny D. Banchik, Attorney at Law
31.07.2018
New partner firm of IPrime in Düsseldorf, Germany
IPrime expands to Düsseldorf, Germany.
01.07.2018
Swiss Federal Tribunal: Disclosure test applicable also for Swiss SPCs
A disclosure test in analogy to CJEU's Medeva decision willl apply for new SPCs in Switzerland